International Biotechnology Trust’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

International Biotechnology Trust’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-67,000	Closed	-$6.89M	–	70
2023 Q2	$6.89M	Buy	+67,000	New	+$7.07M	2.1%	16
2023 Q1	–	Sell	-314,973	Closed	-$35.8M	–	70
2022 Q4	$35.8M	Sell	314,973 -140,000	-31%	-$11.6M	11.07%	1
2022 Q3	$28.2M	Buy	454,973 +432,058	+1,885%	+$30.2M	9.03%	1
2022 Q2	$287K	Sell	22,915 -160,558	-88%	-$15.2M	2.99%	11
2022 Q1	$7.45M	Buy	183,473 +83,600	+84%	+$8.15M	1.68%	24
2021 Q4	$10.8M	Sell	99,873 -138,000	-58%	-$15.1M	2.4%	16
2021 Q3	$26M	Hold	237,873	–	–	6.28%	3
2021 Q2	$22.3M	Sell	237,873 -155,127	-39%	-$14.3M	5.88%	4
2021 Q1	$36.2M	Sell	393,000 -51,000	-11%	-$4.3M	9.57%	1
2020 Q4	$32.5M	Buy	444,000 +55,000	+14%	+$4.09M	8.87%	1
2020 Q3	$30.2M	Sell	389,000 -45,000	-10%	-$3.1M	9.76%	1
2020 Q2	$24M	Buy	434,000 +40,000	+10%	+$1.71M	7.98%	1
2020 Q1	$11.7M	Buy	394,000 +4,000	+1%	+$135K	5.32%	8
2019 Q4	$14.1M	Buy	390,000 +172,000	+79%	+$5.27M	5.08%	6
2019 Q3	$5.94M	Buy	218,000 +90,000	+70%	+$2.33M	2.74%	14
2019 Q2	$3.08M	Hold	128,000	–	–	1.14%	23
2019 Q1	$3.38M	Buy	128,000 +59,000	+86%	+$1.4M	1.25%	26
2018 Q4	$1.06M	Hold	69,000	–	–	0.66%	32
2018 Q3	$1.04M	Hold	69,000	–	–	0.49%	42
2018 Q2	$1.14M	Hold	69,000	–	–	0.44%	43
2018 Q1	$979K	Hold	69,000	–	–	0.38%	52
2017 Q4	$1.01M	Hold	69,000	–	–	0.36%	53
2017 Q3	$876K	Sell	69,000 -100,000	-59%	-$1.27M	0.34%	49
2017 Q2	$2M	Buy	169,000 +84,000	+99%	+$1.04M	0.76%	39
2017 Q1	$1.25M	Hold	85,000	–	–	0.48%	43
2016 Q4	$1.37M	Buy	+85,000	New	+$1.54M	0.62%	32

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

International Biotechnology Trust's HZNP Position: Q3 2023 in Review

International Biotechnology Trust sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 67,000 shares — an estimated $6.89M sold.

International Biotechnology Trust first reported a position in HZNP in Q4 2016 and held it in 26 quarters. The position peaked at $36.2M in Q1 2021. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

International Biotechnology Trust reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
International Biotechnology Trust sold 67,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $6.89M.
International Biotechnology Trust first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2016 and held it in 26 quarters.
International Biotechnology Trust's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $36.2M in Q1 2021.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.